Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar;7(1):1-19.
doi: 10.1159/000487148. Epub 2018 Feb 15.

Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma

Masatoshi Kudo  1
Affiliations
Editorial

Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma

Masatoshi Kudo. Liver Cancer. 2018 Mar.
No abstract available

PubMed Disclaimer

Figures

None
Prof. M. Kudo Editor Liver Cancer
Fig. 1
Fig. 1
Dual inhibition of VEGF and FGF pathways by lenvatinib (cited from Tohyama et al. [13]).
Fig. 2
Fig. 2
Overall survival adjusted by baseline AFP (< 200 ng/mL and ≥200 ng/mL). AFP, α-fetoprotein; HR, hazard ratio.
Fig. 3
Fig. 3
Objective response rate by mRECIST in systemic therapy [11, 24, 25].
Fig. 4
Fig. 4
Objective response rate by RECIST1.1 in systemic therapy [11, 24, 25, 26, 27, 53].
Fig. 5
Fig. 5
Objective response rate by mRECIST TACE and lenvatinib [11, 49, 50, 51].
Fig. 6
Fig. 6
Heterogeneity and treatment strategy of intermediate-stage HCC [52, 54].
Fig. 7
Fig. 7
Treatment strategy for systemic therapy for HCC. Identification of the subgroup that easily develops to TACE failure/refractoriness may be important.
Fig. 8
Fig. 8
Future treatment strategy of bilobar multinodular intermediate-stage HCC.
Fig. 9
Fig. 9
Phase Ib lenvatinib plus pembrolizumab in unresectable HCC.
See this image and copyright information in PMC

References

    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. - PubMed
    1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. - PubMed
    1. Kudo M. Molecular targeted agents for hepatocellular carcinoma: current status and future perspectives. Liver Cancer. 2017;6:101–112. - PMC - PubMed
    1. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067–4075. - PubMed
    1. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31:3517–3524. - PubMed

Publication types